AtCor expands supply contract of SphygmoCor

AtCor Medical signs $0.8 million expansion deal of existing supply contract for SphygmoCor systems with major international pharma firm. SphygmoCor is used to measure the central aortic blood pressures and arterial stiffness noninvasively

Singapore: Australia's AtCor Medical signed an expansion to an existing contract to supply its SphygmoCor systems and clinical trial support services to a major international pharmaceutical company.

SphygmoCor system is used to measure the central aortic blood pressures and arterial stiffness noninvasively. The value of the contract expansion is approximately $0.8 million.

Mr Duncan Ross, CEO, AtCor Medical, said that, "We are delighted to have secured this expansion contract. Our growing pharmaceutical sector sales, including both new contracts and expansion of existing pharmaceutical contracts, continues to validate AtCor's exceptional level of service and support to these important customers."

"The non-invasive measurement of central blood pressure and arterial stiffness is particularly important for drug development, which requires accurate, insightful data to fully understand the efficacy of new drugs," added Mr Ross.